Exhibit 10.28

[***] Certain information in this document has been omitted from this exhibit
because it is both (i) not material and (ii) would be competitively harmful if
publicly disclosed.

Amendment No. 2 to the

Research Collaboration Agreement

of September 17, 2018 by and between

ViaCyte, Inc. and

CRISPR Therapeutics AG

 

This Amendment No. 2 (“Second Amendment”) to the Research Collaboration
Agreement dated September 17, 2018 (the “Agreement”), as amended by Amendment
No. 1 dated April 30, 2019 (“First Amendment”), by and between ViaCyte, Inc.
(“ViaCyte”) and CRISPR Therapeutics AG (“CRISPR”) is effective as of October 21,
2019 (the “Second Amendment Effective Date”).

 

All capitalized terms not otherwise defined in this Second Amendment shall have
the meanings given to such terms in the Agreement.

 

The Agreement is hereby amended as follows:

 

Section 2.8, as amended, is deleted in its entirety and replaced with the
following:

“Research Costs.  All costs incurred by ViaCyte in connection with ViaCyte
Activities will be borne solely by ViaCyte.  All costs incurred by CRISPR in
connection with CRISPR Activities will be borne solely by CRISPR.  For clarity,
all costs incurred by a Party in connection with the activities of such Party in
Exhibit B-3 of the Research Plan (“Exhibit B-3 Costs”) will be borne in
accordance with the above two sentences.  Notwithstanding the above, all costs
incurred by either Party in connection with the activities of the Parties in
Exhibit B-2 of the Research Plan (“Exhibit B-2 Costs”) will be tracked and
reported over the course of the Research Program and shall be borne by
[***].  To be clear, all costs will include equipment, reagent, FTE and facility
costs.  After Establishment of POC or execution of the Joint Development and
Commercialization Agreement, [***] will pay to [***] of the Exhibit B-2 Costs
incurred to date to the extent that either: 1) [***] has agreed in writing in
advance to the amount of such Exhibit B-2 Costs, all criteria of Establishment
of POC have been completed and [***].  Notwithstanding the above, if [***].

Exhibit A is deleted in its entirety and replaced with attached Exhibit A-1, and
any reference in the Agreement to Exhibit A is hereby replaced with a reference
to Exhibit A-1.

Exhibit B-1 is deleted in its entirety.  In Exhibit B, [***]. At the end of
Exhibit B, the attached Exhibit B-2 and Exhibit B-3 are added.

 

All references to the “Agreement” in the Agreement shall hereinafter refer to
the Agreement as amended by this Second Amendment.  Except as specifically
amended by this Second Amendment, the Agreement shall remain in full force and
effect in accordance with its terms.

 

Acknowledged and Agreed by the Parties in accordance with Section 12.5 of the
Agreement as of the Second Amendment Effective Date noted above.

 

VIACYTE, INC.

 

CRISPR THERAPEUTICS AG

 

 

 

 

 

 

 

 

 

 

 

 

 

 

By:

 

/s/ Paul Laikind

 

By:

 

/s/ Rodger Novak

Name:

 

Paul Laikind, PhD

 

Name:

 

Rodger Novak

Title:

 

President & CEO

 

Title:

 

President

 

 

 

--------------------------------------------------------------------------------

[***] Certain information in this document has been omitted from this exhibit
because it is both (i) not material and (ii) would be competitively harmful if
publicly disclosed.

Exhibit A-1

Establishment of POC

[***]

 

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

 

--------------------------------------------------------------------------------

[***] Certain information in this document has been omitted from this exhibit
because it is both (i) not material and (ii) would be competitively harmful if
publicly disclosed.

Exhibit B-2

 

[***]

 

--------------------------------------------------------------------------------

[***] Certain information in this document has been omitted from this exhibit
because it is both (i) not material and (ii) would be competitively harmful if
publicly disclosed.

Exhibit B-3

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]